Implementing New Data and Evolving Standards in Advanced Breast Cancer: Individualizing Treatment for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive

This activity is valid from August 1, 2020 to August 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca, Genentech, Merck Sharp & Dohme Corp.,
Novartis Pharmaceuticals Corporation, and Seattle Genetics

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 231,840 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2020. The incidence in women in the United States is 1 in 8 (about 12 percent). About 40,290 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Fortunately for patients with advanced breast cancer, several new agents, including small molecule tyrosine kinase inhibitors (TKI), are undergoing late stage clinical trials or regulatory review, especially in HER2-positive disease and brain metastases. They have shown the ability to improve safety and efficacy outcomes in the approximately 40% of patients living with HER2-positive advanced breast cancer. 

Upon completion of this activity, participants will be able to:

  • Examine the main signaling pathways and key mechanisms in DNA damage repair and how deficiencies in these pathways can lead to tumor proliferation and growth

  • Compare and contrast efficacy and safety profiles and recent clinical data of current and emerging targeted therapies, including PARP inhibitors, for the treatment of advanced breast cancer

  • Identify patients based on molecular changes and previous therapy that are most likely to benefit from treatments with PARP inhibitors

  • Assess the impact of BRCA1/2 testing on clinical outcomes for patients with advanced breast cancer

  • Explore the role of emerging therapies in the management of HER2-positive advanced breast cancer

  • Analyze evolving data regarding the adverse event profiles of PARP inhibitors currently approved for patients with breast cancers

  • Discuss the managed care considerations of current and emerging PARP inhibitors by exploring where these agents fit into current advanced breast cancer management paradigm

Faculty: Hatem Soliman, MD
Breast Medical Oncology
Chair Clinical Research Advisory Committee
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor, Division of Oncologic Sciences
University of South Florida


Dr. Soliman serves as a consultant to AstraZeneca, Celgene, Eisai, Novartis, and Seattle Genetics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca, Genentech, Merck Sharp & Dohme Corp.,
Novartis Pharmaceuticals Corporation, and Seattle Genetics

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue